Ben Grayson
YOU?
Author Swipe
Residual Effects of Acute and Subchronic Zolpidem Treatments on Attentional Processes in Aged Female Rats Open
Rational Zolpidem, a hypnotic Z‐drug commonly prescribed to promote sleep, is predominantly used over the age of 50. In this elderly population, adverse behavioral disturbances, impaired driving performance, and an increased risk of falls …
The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia Open
Background: Schizophrenia is a serious psychiatric disorder that affects over 24 million people worldwide. Current therapies treat positive symptoms but show little efficacy for negative and cognitive symptoms, which can impact quality of …
Deficits in medial prefrontal cortex parvalbumin expression and distraction-dependent memory in rats and mice in the sub-chronic phencyclidine model for schizophrenia Open
Introduction Cognitive impairments associated with schizophrenia (CIAS) include deficits in declarative memory. This is associated with an inability to maintain information in short-term memory when distracted, and increased sensitivity to…
Oscillatory Deficits in the Sub-Chronic PCP Rat Model for Schizophrenia Are Reversed by mGlu5 Receptor-Positive Allosteric Modulators VU0409551 and VU0360172 Open
The cognitive deficits of schizophrenia are linked to imbalanced excitatory and inhibitory signalling in the prefrontal cortex (PFC), disrupting gamma oscillations. We previously demonstrated that two mGlu5 receptor-positive allosteric mod…
Handling prevents and reverses cognitive deficits induced by sub-chronic phencyclidine in a model for schizophrenia in rats Open
Treatments for schizophrenia are not effective in ameliorating cognitive deficits. Therefore, novel therapies are needed to treat cognitive impairments associated with schizophrenia (CIAS), which are modelled in rats through administration…
Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856 Open
Schizophrenia is a complex psychopathology whose treatment is still challenging. Given the limitations of existing antipsychotics, there is urgent need for novel drugs with fewer side effects. SEP-363856 (SEP-856) is a novel psychotropic a…
Dissociating the effects of distraction and proactive interference on object memory through tests of novelty preference Open
Encoding information into memory is sensitive to distraction while retrieving that memory may be compromised by proactive interference from pre-existing memories. These two debilitating effects are common in neuropsychiatric conditions, bu…
Dissociating the effects of distraction and proactive interference on object memory through tests of novelty preference Open
Encoding information into memory is sensitive to distraction whilst retrieving that memory may be compromised by proactive interference from pre-existing memories. These two debilitating effects are common in neuropsychiatric conditions bu…
(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent Open
Here we describe for the first time the distinctive pharmacological profile for (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752), a new phenyl-pyrrolidine derivative with regioselective central nervous system transmission-enhancin…
Aerobic exercise improves memory and prevents cognitive deficits of relevance to schizophrenia in an animal model Open
Introduction and objectives: Cognitive impairment associated with schizophrenia (CIAS) greatly reduces patients’ functionality, and remains an unmet clinical need. The sub-chronic phencyclidine (scPCP) rat model is commonly employed in stu…
Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory Open
Background: Cognitive deficits and structural brain changes co-occur in patients with schizophrenia. Improving our understanding of the relationship between these is important to develop improved therapeutic strategies. Back-translation of…
T109. MODULATORY ACTIVITY OF THE NOVEL DRUG SEP-363856 ON BRAIN FUNCTION: POTENTIAL APPLICATION FOR THE TREATMENT OF SCHIZOPHRENIA Open
Schizophrenia is a complex and heterogeneous psychiatric disorder. The core features comprise positive and negative symptoms, including hallucinations and impaired motivation, as well as cognitive impairment. Current evidence implicates dy…
T40. GPR52 AGONISTS REPRESENT A NOVEL APPROACH TO TREAT UNMET MEDICAL NEED IN SCHIZOPHRENIA Open
There are currently no treatment options for key symptom domains in certain psychiatric and neurological diseases. For example, antipsychotics effectively treat the positive symptoms of schizophrenia, however both the cognitive impairments…
Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat Open
Background: With current treatments for Alzheimer’s disease (AD) only providing temporary symptomatic benefits, disease modifying drugs are urgently required. This approach relies on improved understanding of the early pathophysiology of A…